Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389086 | 0.91 | MAPK14 (0.45) | MAPK14MAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL12389028 | 0.90 | LMNA (0.44) | MAPK14CCNT1CDK9RAB9AALDH1A1 | |
| SCHEMBL12365404 | 0.88 | MAPK14 (0.54) | MAPK14MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12389005 | 0.87 | MAPK14 (0.41) | MAPK14MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL12389839 | 0.87 | KMT2A (0.44) | KDM4EMAPTCYP1A2ATMNPC1 | |
| SCHEMBL12365083 | 0.87 | MAPK14 (0.48) | MAPK14KDM4EMAPTNPC1RAB9A | |
| SCHEMBL12389756 | 0.87 | MAPT (0.45) | MAPK14KDM4EMAPTRAB9AALDH1A1 | |
| SCHEMBL12365312 | 0.86 | MAPK14 (0.48) | MAPK14KDM4EMAPTNPC1RAB9A | |
| SCHEMBL12389888 | 0.86 | MEN1 (0.45) | MAPK14KDM4EMAPTNPC1RAB9A | |
| SCHEMBL12365406 | 0.86 | MAPK14 (0.49) | MAPK14KDM4EMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | MAPK14 3304/4885KDM4E 1455/4885MAPT 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.